Tempest Therapeutics Inc (nasdaq:TPST) Share Price

Company Profile

Business description
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
Contact
2000 Sierra Point Parkway
Suite 400
BrisbaneCA94005
USA
T: +1 415 798-8589
https://www.tempesttx.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
4

Recommended

Corning’s optical fiber business is thriving, and the Meta deal derisks its supply buildout, but success isn’t guaranteed.

Ananya Chag | 27 April 2026

From AI integration to capital expenditure increases, here’s what we expect in Alphabet’s earnings report.

Malik Ahmed Khan, CFA | 24 April 2026

Santos reports a solid quarter on the back of higher commodity prices - yet the shares look undervalued.

Mark Taylor | 24 April 2026

Index	Last price	Change	% Change
All Ordinaries	8,938.70	10.70	-0.12%
CAC 40	8,141.92	15.90	-0.19%
DAX 40	24,083.53	45.45	-0.19%
Dow JONES (US)	49,167.79	62.92	-0.13%
FTSE 100	10,321.09	57.99	-0.56%
HKSE	25,925.65	52.42	-0.20%
NASDAQ	24,887.10	50.50	0.20%
Nikkei 225	60,194.74	342.62	-0.57%
NZX 50 Index	12,754.66	120.28	-0.93%
S&P 500	7,173.91	8.83	0.12%
S&P/ASX 200	8,710.80	10.40	-0.12%
SSE Composite Index	4,086.14	0.20	-0.00%